1. Home
  2. FORR vs SCLX Comparison

FORR vs SCLX Comparison

Compare FORR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

N/A

Current Price

$6.32

Market Cap

106.6M

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$8.89

Market Cap

59.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FORR
SCLX
Founded
1983
2011
Country
United States
United States
Employees
N/A
30
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.6M
59.6M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
FORR
SCLX
Price
$6.32
$8.89
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
193.4K
29.2K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.38
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.91
$0.18
52 Week High
$11.57
$34.27

Technical Indicators

Market Signals
Indicator
FORR
SCLX
Relative Strength Index (RSI) 47.42 51.01
Support Level $5.02 $7.73
Resistance Level $6.71 $9.00
Average True Range (ATR) 0.40 0.65
MACD 0.11 0.22
Stochastic Oscillator 76.83 60.77

Price Performance

Historical Comparison
FORR
SCLX

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: